MétaCan
Menu
Back to cohort
Record W2884870518 · doi:10.1093/ofid/ofv133.1432

Cost-Effectiveness of Alternative Strategies for Use of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Canadian Adults

2015· article· en· W2884870518 on OpenAlexaboutno aff
Derek Weycker, Mark Atwood, Reiko Sato, Linda Beausoleil, Craig A. Laferrière, Shelly McNeil

Bibliographic record

VenueOpen Forum Infectious Diseases · 2015
Typearticle
Languageen
FieldMedicine
TopicPneumonia and Respiratory Infections
Canadian institutionsnot available
Fundersnot available
KeywordsMedicinePneumococcal conjugate vaccinePneumococcal diseasePathogenic organismPneumococcal infectionsIntensive care medicineStreptococcus pneumoniaePediatricsMicrobiologyAntibiotics

Abstract

fetched live from OpenAlex

Background. The National Advisory Committee on Immunization (NACI) recommends broad use of PCV13 in infants, the 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults ≥65 years, and both vaccines sequentially for adults with immunocompromising conditions. In light of recent PCV13 efficacy results from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), and new sero-epidemiology data on pneumonia caused by PCV13 serotypes in Canadian adults, we examined the economic implications of funding an expanded PCV13 immunization program. Methods. A microsimulation model depicting expected lifetime risks, consequences, and costs of invasive pneumococcal disease (IPD) and all-cause pneumonia (ACP) in Canadian adults was developed. PPV23 effectiveness was based on published literature; PCV13 effectiveness was based on data from CAPiTA. Rates of ACP in different age groups were estimated from the Canadian Institute of Health Information hospital Discharge Abstract Database (CIHI DAD). The pro portion of ACP caused by PCV13 serotypes was estimated from the Serious Outcomes Surveillance (SOS) Network using serotype-specific urinary antigen detection assay. Herd effects were included in the model based on previous observations with PCV7 in Canada. Outcomes and costs were evaluated for three alternative populations: (1) immunocompromised persons 18-99 at model entry (n = 1.4M); (2) immunocompromised persons 18-64 and all persons ≥65 at model entry (n = 6.2M); and (3) immunocompromised and high-risk persons 18-64 and all persons ≥65 at model entry (n = 13.8M). Vaccination strategy compared use of PPV23 alone “current strategy” with use of PCV13 followed by PPV23 “proposed strategy”. Results. Implementing an expanded program with PCV13 followed by PPV23 (in lieu of PPV23 alone) would be cost saving for populations 1 and 2 and highly cost-effective for population 3 (table). Table. Cost-Effectiveness of Proposed Strategies for Expanded Use of PCV13 Conclusion. Implementing the proposed vaccine program with PCV13 followed by PPV23 in Canadian adults would be cost-saving or a highly cost-effective use of scarce healthcare resources. Disclosures. D. Weycker, Pfizer Inc: Research Contractor, Research support; M. Atwood, Pfizer Inc: Consultant, Consulting fee; R. Sato, Pfizer Inc: Employee and Shareholder, Salary; L. Beausoleil, Pfizer Canada Inc: Employee, Salary; C. Laferriere, Pfizer Canada: Employee and Shareholder, Salary; S. A. Mcneil, Pfizer Canada Inc: Grant Investigator and Scientific Advisor, Grant recipient

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.117
Threshold uncertainty score0.805

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.001
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.065
GPT teacher head0.352
Teacher spread0.288 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueOpen Forum Infectious DiseasesSame topicPneumonia and Respiratory InfectionsFrench-language works237,207